Author: Nishtha Mehrotra | EQMint

 

Synopsis: Nifty Pharma has gained 16.25% in 2026 while the Nifty 50 has declined around 14%. Explore the rally, key drivers and risks for investors.

 

Nifty Pharma has emerged as one of India’s strongest-performing sectors in 2026, rising 16.25% year-to-date, while the Nifty 50 has fallen around 14%.

 

An investment of ₹1 lakh in Nifty Pharma at the start of the year would now be worth approximately ₹1.16 lakh, compared with ₹85,750 in the Nifty 50. The difference stands at roughly ₹30,500.

 

View this post on Instagram

A post shared by StockGro (@stock_gro)

The rally reflects pharma’s defensive nature, steady demand for medicines and growth in India’s pharmaceutical market, which expanded 13.5% in Q1 FY27.

 

Nifty Pharma has also outperformed major indices, including the Nifty Midcap 150 and Nifty Smallcap 250. Individual stocks such as Laurus Labs, Gland Pharma and Wockhardt have recorded substantial gains.

 

However, pharma stocks do not outperform consistently. Historical data shows the sector beat the Nifty 500 in only 46% of rolling five-year periods over the past 15 years.

 

Investors should avoid chasing recent gains and consider diversification.

 

Disclaimer: This article is for information purposes only and is not investment advice.

 

For more such information, visit EQMint

 

Join our WhatsApp channel for timely updates: Whatsapp